Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
Publication Date: June 4, 2019
Key Points
Key Points
- Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.
- ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
Treatment
...atment...
...n clinical circumstances ESAs may be offe...
...s should not be offered to patients wit...
...should not be offered to most patients...
...ffered to patients with lower risk myelo...
...with myeloma, non-Hodgkin’s lymphoma,...
...fore offering an ESA, clinicians should con...
...Panel considers epoetin beta and alfa, darbepo...
...e risk of thromboembolism, and clinicians should...
...is recommended that starting and m...
...be increased to the lowest concentration n...
...ould be discontinued in patients who...
...may be used to improve hemoglobin response a...
...Suggested Baseline Investigations for Anemi...
...lt DosingHaving trouble viewing tabl...
...ble 3. Estimated Prices of ESAs and...